PRMT5 Inhibitors in Merkel Cell Carcinoma
Name
higgins-kwh4-sm-bio-2021-thesis.pdf
Description
Thesis PDF
Size
2.27 MB
Format
Adobe PDF
Checksum (MD5)
548ad930cc58542d31a2c5b5d33481ba
Author(s)
Higgins, Kathleen Whitmore
Advisor(s)
Lees, Jacqueline
Date Issued
September 2021
Publisher
Massachusetts Institute of Technology
Abstract
Merkel Cell Carcinoma (MCC) is a rare neuroendocrineskin cancer. Treatment options are limited, and they are largely based on MCC’s similarity to other cancers, rather than original research. Many of these treatments have low efficacy and significant side effects, and the overall prognosis remains bleak. In this thesis, I will propose a new therapeutic strategy for MCC based on chemical inhibition of protein arginine methyltransferase 5 (PRMT5). PRMT5 inhibitors are already being tested in a variety of other solid and liquid tumors to good effect. Our data suggest that PRMT5 inhibitors may be effective in treating a specific subtype of MCC defined by a viral driver and wildtype p53. Treatment inhibits growth in vitro and results in large changes in alternative splicing and more subtle changes in oxidative metabolism. Furthermore, we observe differential alternative splicing of the p53-regulator MDM4, suggesting a possible mechanism for the drug’s greater efficacy in p53-wildtype cell lines.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Terms of Use
In Copyright - Educational Use Permitted
Copyright MIT
Persistent DSpace Link
